Literature DB >> 19328844

Complement protein C3 binding to Bacillus anthracis spores enhances phagocytosis by human macrophages.

Christopher Premanandan1, Craig A Storozuk, Corey D Clay, Michael D Lairmore, Larry S Schlesinger, Andrew J Phipps.   

Abstract

Alveolar macrophages are thought to play a central role in the pathogenesis of inhalational anthrax. Receptors present on macrophages that mediate phagocytosis of Bacillus anthracis spores have yet to be completely defined. To begin to determine if soluble factors that are present in the lung such as immunoglobulin and complement are involved, we characterized the binding of human IgG and C3 to the surface of B. anthracis spores at different concentrations of nonimmune human serum. Furthermore we investigated the uptake of B. anthracis spores by human monocyte-derived macrophages in the presence of nonimmune human serum. Here we show that C3b is bound to B. anthracis spores and is activated through the classical pathway by IgG bound to the spore surface. Furthermore, we show that C3 serves as an opsonin for B. anthracis spores resulting in enhanced phagocytosis by human macrophages. These studies provide evidence that nonimmune serum contains IgG which binds to B. anthracis spores but is not sufficient to initiate phagocytosis. However, surface-bound IgG does initiate the classical pathway of complement activation, which is active in the lung, resulting in deposition of the opsonin C3b on the spore surface.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19328844     DOI: 10.1016/j.micpath.2009.03.004

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  8 in total

1.  Immune cell-derived c3 is required for autoimmune diabetes induced by multiple low doses of streptozotocin.

Authors:  Marvin Lin; Na Yin; Barbara Murphy; M Edward Medof; Stephan Segerer; Peter S Heeger; Bernd Schröppel
Journal:  Diabetes       Date:  2010-06-28       Impact factor: 9.461

2.  Bacillus anthracis interacts with plasmin(ogen) to evade C3b-dependent innate immunity.

Authors:  Myung-Chul Chung; Jessica H Tonry; Aarthi Narayanan; Nathan P Manes; Ryan S Mackie; Bradford Gutting; Dhritiman V Mukherjee; Taissia G Popova; Fatah Kashanchi; Charles L Bailey; Serguei G Popov
Journal:  PLoS One       Date:  2011-03-25       Impact factor: 3.240

3.  Complement C5 inhibition protects against hemolytic anemia and acute kidney injury in anthrax peptidoglycan-induced sepsis in baboons.

Authors:  Ravi Shankar Keshari; Narcis Ioan Popescu; Robert Silasi; Girija Regmi; Cristina Lupu; Joe H Simmons; Alonso Ricardo; K Mark Coggeshall; Florea Lupu
Journal:  Proc Natl Acad Sci U S A       Date:  2021-09-14       Impact factor: 11.205

4.  Serum-Mediated Cleavage of Bacillus anthracis Protective Antigen Is a Two-Step Process That Involves a Serum Carboxypeptidase.

Authors:  David L Goldman; Edward Nieves; Antonio Nakouzi; Johanna Rivera; Ei Ei Phyu; Than Htut Win; Jacqueline M Achkar; Arturo Casadevall
Journal:  mSphere       Date:  2018-06-27       Impact factor: 4.389

5.  C3 Opsonization of Anthrax Bacterium and Peptidoglycan Supports Recognition and Activation of Neutrophils.

Authors:  Narcis I Popescu; Ravi S Keshari; Jackie Cochran; K Mark Coggeshall; Florea Lupu
Journal:  Microorganisms       Date:  2020-07-13

Review 6.  Bacillus anthracis factors for phagosomal escape.

Authors:  Fiorella Tonello; Irene Zornetta
Journal:  Toxins (Basel)       Date:  2012-07-10       Impact factor: 4.546

Review 7.  From mouth to macrophage: mechanisms of innate immune subversion by Mycobacterium avium subsp. paratuberculosis.

Authors:  Ryan J Arsenault; Pekka Maattanen; Joanna Daigle; Andrew Potter; Philip Griebel; Scott Napper
Journal:  Vet Res       Date:  2014-05-15       Impact factor: 3.683

8.  Bacillus anthracis Poly-γ-D-Glutamate Capsule Inhibits Opsonic Phagocytosis by Impeding Complement Activation.

Authors:  Shikhar Sharma; Rakesh Bhatnagar; Deepak Gaur
Journal:  Front Immunol       Date:  2020-03-31       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.